<DOC>
	<DOCNO>NCT02770404</DOCNO>
	<brief_summary>This Phase 1 , randomize , double-blind , single-center , placebo-controlled , sequential-cohort study least 60 healthy adult male female subject . Subjects Cohorts 1 5 randomly assign 8:2 allocation receive active placebo treatment . Subjects Cohort 6 randomly assign 1:1 allocation receive IV dose nafithromycin single oral dose nafithromycin crossover period . Subjects Cohorts 1 , 2 , 3 receive single dose 100 , 200 , 400 mg , respectively , nafithromycin match placebo Day 1 .</brief_summary>
	<brief_title>A Phase 1 Pharmacokinetic Study Single-Ascending Doses Intravenous Nafithromycin Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Male female subject 18 55 year age , inclusive , creatinine clearance â‰¥80 mL/minute ( CockcroftGault method ) . 1 . Clinically relevant pathology systemic disorder/major surgery opinion investigator would confound subject 's participation followup clinical study . 2 . Drug food allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>